ModifiedHealth NetPolicy CP PHAR.216

Factor VIII/von Willebrand factor products (Alphanate, Humate-P, Wilate, Vonvendi)

Authorization and medical necessity criteria for human FVIII–VWF complexes (Alphanate, Humate-P, Wilate) and recombinant von Willebrand factor (Vonvendi) for Hemophilia A and von Willebrand disease; applies to members covered by Health Net lines of business listed in the policy.

Policy Summary

PayerHealth Net

PolicyFactor VIII/von Willebrand factor products (Alphanate, Humate-P, Wilate, Vonvendi)

Policy CodePolicy CP PHAR.216

Change TypeMultiple clarifications and indication additions

Effective DateMay 1, 2016

Next Review Date

Key ActionSubmit prior authorization with supporting documentation (office notes, labs and current body weight when requesting therapy or dose increase).

SourceLink

POLICY UPDATE CHANGES

Clarified requirement for coverage of Wilate for routine prophylaxis: FVIII activity level or documentation of bleed history requirement applies only to requests for new starts to routine prophylactic therapy.

Added newly approved indication for Vonvendi for routine prophylaxis and pediatric perioperative on-demand extension.

Extended initial and continued authorization durations for hemophilia and von Willebrand disease prophylaxis from 3 months to 12 months for HIM Texas.

Authorization durations updated across lines of business in 2024–2025 reviews (prophylaxis and surgical/acute bleeding durations adjusted by program).

For continued therapy, the member's current weight is required only if a higher dose is being requested.

Desmopressin acetate trial requirement revised to apply only to patients age ≥ 2 years.

Removed the term 'life-threatening' from the criterion 'life-threatening or serious bleed' to avoid misinterpretation.

Updated sites of serious bleeds per WFH guideline in Appendix D.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: Initial Therapy — Hemophilia A

Covered when ALL of the following are met:

Initial Hemophilia A criteria: 1) Diagnosis of congenital hemophilia A (FVIII deficiency); 2) Request is for Alphanate, Humate-P, or Wilate; 3) Prescribed by or in consultation with a hematologist; 4) Request is for one of: control/prevention of bleeding episodes; perioperative management (Alphanate only); or routine prophylaxis to reduce bleeding frequency (Wilate only); 5) For routine prophylaxis requests with Wilate in members who have not previously used Wilate for routine prophylaxis, member has experienced at least one serious spontaneous bleed OR meets the alternate condition listed in policy; 6) Member has severe hemophilia (FVIII coagulant activity level ≤ 1%); 7) For patients age ≥ 2 years with FVIII coagulant activity ≤ 5%: failure of desmopressin acetate is required unless contraindicated, clinically significant adverse effects occur, or an appropriate formulation is unavailable (Illinois HIM exception applies as specified); 8) Documentation of the member's current body weight (kg) is provided; 9) Requested dose does not exceed the FDA‑approved maximum recommended dose for the relevant indication.

inv-02: Initial Therapy — Von Willebrand Disease

Covered when ALL of the following are met:

Initial VWD criteria: 1) Diagnosis of von Willebrand disease (VWD); 2) Prescribed by or in consultation with a hematologist; 3) For patients age ≥ 2 years with VWD type 1 or 2 (except type 2B): failure of desmopressin acetate is required prior to authorization unless contraindicated, clinically significant adverse effects occur, or an appropriate formulation is unavailable (Illinois HIM exception applies as specified); 4) Request is for an approved use per product labeling: perioperative management; treatment of bleeding episodes (Humate‑P, Vonvendi, Wilate as applicable); or routine prophylaxis where age/product limits apply (Vonvendi initiation per label, Wilate prophylaxis age criteria); 5) Documentation of the member's current body weight (kg); 6) Requested dose does not exceed the FDA‑approved maximum recommended dose for the relevant indication.

inv-03: Continuation Therapy

Covered when ALL of the following are met:

Continued therapy criteria: 1) Member is currently receiving the medication via the Centene benefit OR has previously met the policy's initial approval criteria (continuity of care regulations apply per state/product addenda where relevant); 2) Member is responding positively to therapy (clinical benefit demonstrated); 3) If the request is for a dose increase: (a) documentation that the new dose does not exceed the FDA‑approved maximum recommended dose for the indication, and (b) documentation of the member's current body weight in kilograms when requesting a higher dose.

inv-03: Covered indications and dosing

Coverage and dosing differ by diagnosis (hemophilia A vs VWD), indication (minor, moderate, major, perioperative, routine prophylaxis) and product — covered when product‑ and indication‑specific dosing and contraindications are met.

Indications covered: Treatment and control of bleeding episodes, perioperative management, and routine prophylaxis for hemophilia A and von Willebrand disease as specified per product dosing tables.

Product dosing examples - Alphanate: Minor: 15 IU/kg IV every 12 hours; Moderate: 25 IU/kg IV every 12 hours; Major: 40–50 IU/kg IV initial then 25 IU/kg IV every 12 hours; Perioperative: pre‑op 40–50 IU/kg IV once, post‑op 30–50 IU/kg IV every 12 hours; Maximum dose: 100 IU/kg/day.

Product dosing examples - Humate‑P: Moderate: 25 IU/kg loading dose to achieve ~50% FVIII:C then 15 IU/kg IV every 8–12 hours; Major: 40–50 IU/kg IV initial then 20–25 IU/kg IV every 8 hours to maintain 80–100% for ~7 days; VWD dosing varies by type with loading and maintenance regimens as specified in labeling; Maximum reported up to ~240 IU/kg/day in some regimens.

inv-05: Updated coverage criteria

Coverage and authorization criteria updated for initiation and continuation of prophylaxis and for specific product indications.

Wilate routine prophylaxis (new starts): For new starts of Wilate for routine prophylaxis, documentation of an FVIII coagulant activity level OR documentation of bleed history is required.

Requirement applies only to new starts of routine prophylaxis per policy clarification.

Continued therapy dosing info: For continued therapy, the member's current weight is required only when requesting a higher dose; routine renewals without dose increase do not require updated weight documentation.

Clarified operational requirement for renewals.

Desmopressin trial for VWD therapies: Desmopressin acetate trial requirement revised to apply only to patients age ≥ 2 years; when applicable per line of business, a trial of desmopressin is required prior to certain VWD therapies unless contraindicated or unavailable.age >= 2 years

Alphanate is not indicated for patients with severe von Willebrand disease (type 3) who are undergoing major surgery.

Requests for non‑FDA approved indications that are not specifically addressed in this policy are excluded from authorization unless the provider supplies sufficient documentation of efficacy and safety per the applicable off‑label use policies (see CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid) or evidence of coverage documents. For uses that involve formulary or PDL status, follow the relevant no‑coverage or non‑formulary policies (e.g., CP.CPA.190, HIM.PA.33/HIM.PA.103, CP.PMN.255/CP.PMN.16) as applicable.

Historically, the policy included a redirection to Hemlibra for members identified as high FVIII utilizers; this redirection was removed pending cost‑savings analysis during the 1Q 2022 annual review while data were evaluated.

Any requested use of the listed products that is not expressly covered under the diagnoses and indications sections of this policy should be processed according to the payer's no‑coverage, non‑formulary, or off‑label use policies. Providers must refer to the applicable line‑of‑business policies (e.g., CP.CPA.190, HIM.PA.33/HIM.PA.103, CP.PMN.255/CP.PMN.16) or the off‑label use policy (CP.CPA.09, HIM.PA.154, CP.PMN.53) for authorization guidance.

There are no explicit statements in the provided policy text that label any specific listed use as universally not medically necessary; determinations for uses not listed should follow the payer's no‑coverage/non‑formulary/off‑label policies as referenced elsewhere in this policy.

Codes, Dosing Thresholds, and Definitions

Codes referencedmixed

N/A	No specific CPT/HCPCS/ICD-10/NDC codes listed in this part of the document.

Covered HCPCS J-codes referencedHCPCS

J7183	Injection, von Willebrand factor complex (human) Wilate, 1 IU vWF:RCo
J7186	Injection, antihemophilic FVIII/von Willebrand factor complex (human), per FVIII
J7187	Injection, von Willebrand factor complex (Humate-P) per IU VWF:RCo
J7179	Injection, von Willebrand factor (recombinant) (Vonvendi) per 1 IU vWF:RCo

inv-13: Severe hemophilia threshold

Severe hemophilia thresholdDefined in policy as factor VIII (FVIII) coagulant activity level of 1% (FVIII ≤ 1%).

Usage contextRequired as an eligibility threshold for initial approval of therapies for congenital hemophilia A (e.g., Wilate prophylaxis new starts require documentation of severe hemophilia where applicable).

DocumentationProvider must include laboratory documentation of FVIII activity to demonstrate FVIII ≤ 1% when claiming severe hemophilia.

inv-14: Product-specific maximum dosing

Alphanate maximumMaximum dose: 100 IU/kg/day (product-specific dosing: minor/moderate/major regimens described per indication).

Humate-P maximum

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization

Prior Authorization Required

Prior authorization required — requests for Alphanate, Humate-P, Vonvendi, and Wilate must have prior authorization and meet medical necessity per policy. Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria.

Applies to factor VIII–von Willebrand factor complexes and von Willebrand factor products listed in policy
Prior authorization required for initial and continued therapy

Documentation Required

Documentation Required — include weight and clinical records

Provider must submit documentation (office notes, lab results, bleed history, and current weight in kg when requesting therapy or dose changes). Missing supporting documentation may result in denial of the request.

Include current body weight (kg) for initial requests and when requesting a higher dose

Clinical Background and Scope

Human factor VIII–von Willebrand factor (FVIII–VWF) concentrates (Alphanate, Humate‑P, Wilate) and the recombinant von Willebrand factor Vonvendi are indicated in product labeling for control and prevention of bleeding, perioperative management, treatment of spontaneous or trauma‑induced bleeding, and routine prophylaxis to reduce bleed frequency in eligible patients with hemophilia A or von Willebrand disease. Product‑specific indications and dosing differ: for example, Alphanate is used for Hemophilia A including perioperative management; Humate‑P and Wilate are used for treatment of bleeding episodes and prophylaxis per age and indication; Vonvendi (recombinant VWF) has labeled uses for treatment and has been expanded to include routine prophylaxis and pediatric perioperative on‑demand management per recent updates. Perioperative and major bleeding regimens typically involve higher initial loading doses followed by maintenance dosing, and maximum daily dosing limits vary by product and indication.

Clinical Definitions and Terms Used

inv-29: Severe hemophilia definition

DefinitionSevere hemophilia is defined in this policy as a factor VIII (FVIII) coagulant activity level of 1%.

Role in criteriaUsed as an eligibility requirement for initial approval of therapy for congenital hemophilia A (documented FVIII ≤ 1%).

Documentation requirementLaboratory FVIII activity result must be provided to substantiate the severe hemophilia designation when requested.

inv-30: Spontaneous bleed / Serious bleeding episode

Spontaneous bleedA bleeding episode that occurs without apparent cause and is not the result of trauma (policy Appendix D).

Serious bleeding episode — sites includedSerious bleeding episodes include intracranial; neck/throat; gastrointestinal; joints (hemarthrosis); muscles (deep compartments such as iliopsoas, calf, forearm); and mucous membranes of the mouth, nose, and genitourinary tract.

Policy Summary

PayerHealth Net

PolicyFactor VIII/von Willebrand factor products (Alphanate, Humate-P, Wilate, Vonvendi)

Policy CodePolicy CP PHAR.216

Change TypeMultiple clarifications and indication additions

Effective DateMay 1, 2016

Next Review Date

Key ActionSubmit prior authorization with supporting documentation (office notes, labs and current body weight when requesting therapy or dose increase).

SourceLink

On This Page

inv-15: Age threshold for desmopressin trial

Age threshold for desmopressin trial>= 2 years — desmopressin acetate trial requirement revised to apply only to patients age ≥ 2 years for eligible VWD indications (type 1 or 2, except 2B).

Desmopressin formulations referencedIV injection: 0.3 mcg/kg IV (repeat every 48 hours as indicated); Intranasal: Stimate nasal spray dosing per spray and body weight as described in dosing guidance.

Step-therapy exceptionsDesmopressin trial may be bypassed if contraindicated, clinically significant adverse effects occur, or appropriate formulation is unavailable (Illinois HIM exception applies as noted).

inv-31: Desmopressin (DDAVP)

Therapeutic roleDesmopressin (DDAVP; Stimate nasal spray or generic injection) is an alternative therapy for von Willebrand disease type 1 or 2 (except type 2B) when FVIII coagulant activity levels meet criteria; used as a step prior to VWF products in eligible patients.

IV dosingInjection dosing: 0.3 mcg/kg IV (may be repeated every 48 hours as indicated).

Intranasal dosingNasal spray dosing: one spray in one nostril for patients ~50 kg; one spray in each nostril for larger patients (may repeat based on laboratory response and clinical condition); maximum intranasal dose described as one spray in each nostril.